Startup profile · funding coverage
Pearl Diagnostics funding, valuation and investors
Johns Hopkins spinout commercializing noninvasive urine assays for lung infections (Aspergillus, Pseudomonas).
Keep track of Pearl Diagnostics
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series A
$11.2M · March 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$11M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series a · Baltimore, MD
Overview
Pearl Diagnostics develops noninvasive in vitro diagnostics for lung infections by detecting microbial extracellular vesicles in urine. Spun out of Johns Hopkins University in 2014, the company received FDA 510(k) clearance for its MycoMEIA Aspergillus assay in August 2025 and closed an $11.2M Series A in March 2026 (SEC filing) to commercialize in the U.S., with CE approval enabling EU sales.
Why Pearl Diagnostics is interesting
Rare Baltimore diagnostics commercialization: FDA 510(k) clearance for MycoMEIA Aspergillus assay (Aug 2025) plus $11.2M Series A (Mar 2026, SEC filing) to launch U.S. sales — EV-based lung infection detection, not another generic PCR panel.
Product & use cases
Noninvasive diagnostic for fungal infections — moving from regulatory clearance to U.S. and European commercial launch.
- Clinical fungal infection detection without invasive sampling
- Hospital and lab diagnostic workflows post-FDA clearance
Key facts
- Johns Hopkins spinout (2014); HQ Baltimore
- FDA 510(k) clearance: MycoMEIA Aspergillus assay (Aug 2025)
- Series A (Mar 2026): $11.2M per SEC filing (Technical.ly coverage)
- CEO Eric Gornstein joined for commercialization push
Funding history (newest first)
Series A
2026-03 $11.2MSource: https://technical.ly/entrepreneurship/pearl-diagnostics-raises-series-a-maryland-money-moves/
Competitive landscape
Edge: Regulatory milestones on a Hopkins science base — commercial bet is GTM execution, not basic science risk.
-
Culture-based fungal panels incumbent
Standard of care; Pearl pitches noninvasive alternative.
-
Other molecular fungal tests direct
Competing cleared diagnostics.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Pearl Diagnostics's financing or category context.
FAQs about Pearl Diagnostics
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.